Argenx enters into agreement to acquire priority review voucher

Amsterdam, the netherlands – november 30, 2022 – argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced an agreement to acquire a u.s. food and drug administration (fda) priority review voucher (prv) for $102 million. a prv entitles the holder to fda priority review of a single biologics license application (bla), which reduces the target review period and may lead to an expedited approval.
ARGX Ratings Summary
ARGX Quant Ranking